|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||33.69 - 34.04|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||22.19|
|Forward Dividend & Yield||0.90 (2.69%)|
|1y Target Est||N/A|
The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]
Acorda scraps development of a key Parkinson's disease candidate, tozadenant. With the discontinuation, investors' focus once again shifts to the Parkinson's space.
The Zacks Analyst Blog Highlights: Walmart, NVIDIA, Procter & Gamble, Phillips 66 and AstraZeneca
US civil rights activist Jesse Jackson disclosed that he has been diagnosed with Parkinson’s disease. Unfortunately for Jackson, and more than 10 million worldwide living with Parkinson's, there's no cure. However, a new partnership between AstraZeneca and Berg believes AI will be able to prevent it
Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial. It is a significant milestone for physicians, patients and investors, who are trying to assess the competitive landscape as drugmakers race to develop better ways to fight tumours in previously untreated lung cancer.
Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial.
AstraZeneca’s (AZN) Oncology segment reported revenues of ~$1 billion during 3Q17, a 19% growth at constant exchange rates.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AstraZeneca Plc Here are 5 ETFs with the largest exposure to AZN-US. Comparing the performance and risk of AstraZeneca Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
AstraZeneca’s (AZN) Respiratory segment is one of its key growth platforms. For 3Q17, the segment's revenues fell 2% at constant exchange rates to ~$1.1 billion.
Ever since its cholesterol-fighting drug Lipitor lost the crux of its patent protection back in 2011, Pfizer Inc. (NYSE:PFE) investors have approached PFE stock with caution. Early this week, Purkiss made a point of saying sales of Ibrance is being underestimated, suggesting that rather than achieving just a little less than $7 billion in revenue in 2023, it could actually produce nearly $13-billion worth of business that year as its approved uses were expanded and caregivers saw its efficacy.
This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.
Brilinta reported 36% growth in revenues at constant exchange rates to $284 million, while foreign exchange impacted its revenues positively by 1% during 3Q17.
AstraZeneca Plc is in talks to settle a Texas lawsuit claiming that the company fleeced the state’s Medicaid program by fraudulently marketing one of its top drugs, according to court filings.
AstraZeneca's (AZN) overall revenue growth was 9%, driven by a substantial growth in externalization revenues to $1.~4 billion, partially offset by a 2% fall in product sales.
In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.
AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it. The U.S. Food and Drug Administration's (FDA) decision to endorse benralizumab, which will be marketed under the name Fasenra, follows a positive recommendation for the product in Europe on Friday. Shares in AstraZeneca were 1 percent higher on Wednesday following the overnight news.
Categories: Yahoo FinanceGet free summary analysis AstraZeneca Plc reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of AstraZeneca Plc – Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc Sponsored ADR, Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Biogen Inc. and Celgene ... Read more (Read more...)
Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.